Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/194392
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Adaptive and innate immune cells play a crucial role as regulators of cancer development. Inflammatory cells in blood flow seem to be involved in pro-tumor activities and contribute to breast cancer progression. Circulating lymphocyte ratios such as the platelet-lymphocytes ratio (PLR), the monocyte-lymphocyte ratio (MLR) and the neutrophil-lymphocyte ratio (NLR) are new reproducible, routinely feasible and cheap biomarkers of immune response. These indexes have been correlated to prognosis in many solid tumors and there is growing evidence on their clinical applicability as independent prognostic markers also for breast cancer. In this review we give an overview of the possible value of lymphocytic indexes in advanced breast cancer prognosis and prediction of outcome. Furthermore, targeting the immune system appear to be a promising therapeutic strategy for breast cancer, especially macrophage-targeted therapies. Herein we present an overview of the ongoing clinical trials testing systemic inflammatory cells as therapeutic targets in breast cancer.
Matèries
Matèries (anglès)
Citació
Citació
GIANNI, Caterina, PALLESCHI, Michela, SCHEPISI, Giuseppe, CASADEI, Chiara, BLEVE, Sara, MERLONI, Filippo, SIRICO, Marianna, SARTI, Samanta, CECCONETTO, Lorenzo, DI MENNA, Giandomenico, SCHETTINI, Francesco, DE GIORGI, Ugo. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. _Frontiers In Oncology_. 2022. Vol. 12, núm. 882896. [consulta: 20 de gener de 2026]. ISSN: 2234-943X. [Disponible a: https://hdl.handle.net/2445/194392]